Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

R esearchers have developed a ligand-protected direct hydrogen reduction strategy to prepare zeolite-confined Pt-Pd bimetallic cluster catalysts. These catalysts efficiently facilitate hydrogen ...

The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

The most advanced molecules in its pipeline target the IC proteins CD47, a ligand of signal-regulatory protein-α (SIRPα), and PD-L1, a ligand of programmed cell death protein 1 (PD-1 ...

See α-Synuclein. Candidate tracer SY08 detects α-synuclein deposits in the brainstem (right) and parietal cortex (left) of ...

“Historically, patients who progress on PD-(L)1 therapy are estimated to have a ≤5% likelihood of response to PD-(L)1 rechallenge, making this an extremely difficult-to-treat ...

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp.(CHRO) to combine Ligand's wholly owned subsidiaries, Pelthos ...